← Back to Search

Anti-viral

Treatment Arm for Chronic Hepatitis C

Phase 4
Waitlist Available
Research Sponsored by Peter J. Ruane, M.D., Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up sustained virologic response 12 weeks after treatment completion
Awards & highlights

Study Summary

This study is evaluating the safety and efficacy of a 12 week treatment LDV/SOF FDC in patients with Chronic GT1 or GT4 HCV infection and autoimmune disease

Eligible Conditions
  • Chronic Hepatitis C

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~sustained virologic response 12 weeks after treatment completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and sustained virologic response 12 weeks after treatment completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
SVR12 (Sustained Virologic Response)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
12 Week treatment with LDV/SOF FDC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LDV/SOF FDC
2014
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

Gilead SciencesIndustry Sponsor
1,084 Previous Clinical Trials
843,439 Total Patients Enrolled
Peter J. Ruane, M.D., Inc.Lead Sponsor
2 Previous Clinical Trials
60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease
2016. "Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02691728.
All > Autoimmune Hemolytic Anemia
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top